Top Page
CStone Pharmaceuticals
(2616)
CStone Pharmaceuticals (2616) vs. iShares MSCI Hong Kong ETF (EWH)
CStone Pharmaceuticals Business Overview & Revenue Model
CStone Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 177.77M | 407.20M | 463.84M | 481.36M | 243.72M | 1.04B |
| Gross Profit | 21.73M | 240.15M | 304.30M | 278.38M | 136.89M | 797.41M |
| EBITDA | -216.63M | -76.43M | -297.23M | -849.66M | -1.90B | -1.20B |
| Net Income | -242.00M | -91.21M | -367.23M | -902.68M | -1.92B | -1.22B |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 690.10M | 672.94M | 1.05B | 1.04B | 1.73B | 3.39B |
| Total Debt | 391.37M | 355.97M | 363.45M | 286.29M | 174.20M | 83.86M |
| Total Liabilities | 876.86M | 1.03B | 1.21B | 1.19B | 1.06B | 808.29M |
| Stockholders Equity | 315.04M | 363.87M | 456.83M | 449.33M | 1.21B | 2.95B |
Cash Flow | ||||||
| Free Cash Flow | -156.05M | -343.18M | -653.89M | -714.29M | -1.63B | -579.52M |
| Operating Cash Flow | -156.05M | -343.18M | -588.84M | -612.47M | -1.48B | -508.07M |
| Investing Cash Flow | -149.95M | -247.68M | 619.61M | 365.12M | -826.55M | 1.18B |
| Financing Cash Flow | 22.58M | -12.90M | 388.36M | 28.47M | 92.30M | 1.39B |
CStone Pharmaceuticals Technical Analysis
CStone Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.74B | 48.45 | 6.73% | ― | 23.37% | ― | |
53 Neutral | HK$10.44B | 40.11 | 13.34% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$11.87B | 17.20 | 35.80% | ― | 59.70% | 239.97% | |
42 Neutral | HK$8.89B | -18.93 | -95.84% | ― | -55.64% | -158.67% | |
39 Underperform | HK$2.63B | -3.73 | -129.05% | ― | ― | -18.99% |
CStone Pharmaceuticals Corporate Events
CStone Pharmaceuticals announced that the European Commission has approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval expands sugemalimab’s indication to cover a broader spectrum of NSCLC, providing a new treatment option for patients in Europe. The achievement highlights CStone’s commitment to enhancing global accessibility of its therapies and addressing unmet medical needs in oncology.
CStone Pharmaceuticals has announced the international debut of its bispecific antibody, CS2015, at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI). This marks the first presentation of CS2015 at an international conference, highlighting its potential impact on the treatment of type 2 inflammation. The molecule’s unique design targets OX40L and TSLP, crucial regulators of inflammation, and offers a strong developability profile for scalable manufacturing, indicating significant advancements in therapeutic options for autoimmune and inflammatory diseases.
CStone Pharmaceuticals announced the approval of their Investigational New Drug application by the China National Medical Products Administration for Phase II clinical trials of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, for advanced solid tumors. This approval is expected to accelerate the clinical development of CS2009, which is currently enrolling patients in Australia and will soon expand to China and the United States, potentially strengthening CStone’s position in the biopharmaceutical industry and offering new therapeutic options for various cancers.
CStone Pharmaceuticals announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational efficiency.
CStone Pharmaceuticals has announced the appointment of Ms. Fang Xie as an independent non-executive director and chairperson of the audit committee, effective November 1, 2025. Ms. Xie brings over 30 years of experience in operational finance and management consulting, having served in various leadership roles in prominent companies. Her appointment follows the resignation of Ms. Yip Betty Ho, who stepped down to focus on personal commitments. The changes in the board are expected to strengthen CStone’s governance and strategic direction, potentially impacting its market positioning positively.
CStone Pharmaceuticals announced that its CEO, Dr. Jianxin Yang, along with senior management, has increased their shareholding in the company by purchasing 1,000,000 shares, with Dr. Yang acquiring 700,000 shares. This move underscores their confidence in the company’s long-term investment value and growth prospects, as well as their commitment to its future business success. The board views this increase in shareholding as a sign of strong belief in the company’s ability to maintain steady operations and achieve rapid growth, which could positively impact stakeholder confidence.
CStone Pharmaceuticals announced the first disclosure of preliminary Phase I data for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, at the 2025 ESMO Annual Congress. The study, conducted in Australia and China, evaluates the safety and antitumor activity of CS2009 in patients with advanced solid tumors, showing favorable safety and tolerability with no dose-limiting toxicity reported. This development marks a significant step in CStone’s efforts to innovate cancer treatment, potentially enhancing its industry positioning and offering new hope for stakeholders involved.
CStone Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of sugemalimab as a monotherapy for unresectable stage III non-small cell lung cancer (NSCLC) in Europe. This development, based on the pivotal Phase III GEMSTONE-301 study, could solidify sugemalimab’s role as a core immunotherapy for lung cancer, enhancing its market presence and commercial potential. If approved, it will become the second PD-(L)1 antibody available in Europe for stage III NSCLC, addressing a critical unmet need and bringing new hope to patients.
CStone Pharmaceuticals announced its participation in the 2025 European Society for Medical Oncology Congress, where it will present data from its ongoing clinical trials. The company will showcase the world’s first clinical data for a PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, in advanced solid tumor patients, and provide an update on the ROR1-targeting ADC, CS5001. These presentations highlight CStone’s commitment to advancing innovative cancer therapies and may enhance its positioning in the biopharmaceutical industry.
CStone Pharmaceuticals announced the enrollment of the first patient in Australia for their global Phase II clinical trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody. This trial, which will expand to the United States, aims to evaluate the drug’s safety, tolerability, and efficacy across multiple tumor types, including lung, liver, colorectal, ovarian, breast, and cervical cancers. The Phase I study showed promising results with favorable safety and significant antitumor activity, suggesting potential advancements in treatment options for various cancers.
CStone Pharmaceuticals has appointed Mr. Kenneth Howard Jarrett as an independent non-executive director, effective September 23, 2025. Mr. Jarrett brings over 40 years of experience in government and business relations, strategic planning, and key relationship building, having held significant positions in U.S. consulates and private sector organizations. His appointment is expected to strengthen CStone’s strategic and audit committees, potentially enhancing the company’s governance and strategic direction. This move may positively impact CStone’s standing in the biopharmaceutical industry, offering stakeholders confidence in its leadership and future growth prospects.
CStone Pharmaceuticals has announced the composition of its board of directors and their respective roles within the company. This announcement highlights the company’s leadership structure, which includes a mix of executive, non-executive, and independent directors, and outlines the membership of various board committees, reflecting the company’s commitment to governance and strategic oversight.
CStone Pharmaceuticals announced that its bispecific antibody CS2015, targeting OX40L and TSLP, will be showcased at the ACAAI 2025 Annual Scientific Meeting in Orlando. This novel therapeutic agent aims to address Type 2 inflammatory diseases such as atopic dermatitis, asthma, and COPD. The presentation highlights CStone’s strategic focus on innovative treatments for autoimmune and inflammation conditions, potentially enhancing its market position and offering new solutions for patients.